Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002377 | 0.85 | CPT1A (0.47) | CPT1ACYP2C9ALDH1A1NPC1RAB9A | |
| SCHEMBL12569914 | 0.85 | KDM4E (0.44) | CPT1ACYP2C9P2RY12OGAALPL | |
| SCHEMBL2001117 | 0.84 | CPT1A (0.56) | CPT1ACYP2C9RORCCPT2NPC1 | |
| SCHEMBL12569920 | 0.82 | RORC (0.57) | CPT1ACYP2C9RORCALPLALDH1A1 | |
| SCHEMBL2000796 | 0.81 | CYP2C9 (0.55) | CPT1ACYP2C9RORC | |
| SCHEMBL4565364 | 0.81 | CYP2C9 (0.55) | CPT1ACYP2C9RORCNPC1 | |
| SCHEMBL2002383 | 0.80 | CPT1A (0.43) | CPT1ACYP2C9RORCALDH1A1MAPK1 | |
| SCHEMBL2004965 | 0.75 | HDAC1 (0.46) | CPT1ACYP2C9 | |
| SCHEMBL2003739 | 0.74 | CPT1A (0.47) | CPT1ACYP2C9RORCCPT2CPT1B | |
| SCHEMBL1999908 | 0.73 | CPT1A (0.47) | CPT1ACYP2C9RORCCPT2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | CPT1A 3067/4885CYP2C9 346/4885RORC 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.